U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020923) titled 'Monthly Dosing of Atacicept in IgAN' on May 13.
Brief Summary: This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Study Start Date: May 29
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy (IgAN)
Berger Disease
Intervention:
DRUG: Atacicept
Drug: Atacicept
Recruitment Status: RECRUITING
Sponsor: Vera Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....